Etid klinik pou Myozit nan Texas
7 etid pou Myozit ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Integrative Rheumatology of South Texas, Edinburg
- Arthritis & Rheumatology Research Institute, PLLC, Frisco
- Integrative Rheumatology of South Texas, Harlingen
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05895786Descartes-08 in Autoantibody Myositis
- National Neuromuscular Research Institute, Austin
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Dallas
- Nkarta Investigational Site, Houston
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Arlington, Arlington
- Artiva Investigational Site Bellaire, Bellaire
- Artiva Investigational Site Irving, Irving
- ak 4 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
- Austin Neuromuscular Center, Austin
- Austin Neuromuscular Center, Austin
Ap rekriteFaz 1 bonè
Laj 45 a 75 · Tout sèks · Mizajou Jan 16, 2026 · NCT06479863Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.